Please enter exact key words
A Potential First-in-class Therapeutic Antibody

for the Treatment of Hyperparathyroidism and Humoral Hypercalcemia of Malignancy

Home / Available Projects / A Potential First-in-class Therapeutic Antibody
Drug Name GPCR-targeted Project 004

Parathyroid hormone/parathyroid hormone-related peptide receptor, also known as parathyroid hormone 1 receptor (PTH1R) is a member of the B GPCR family and is the primary receptor of two ligands, parathyroid hormone (PTH) and parathyroid related protein (PTHrP). Hypercalcemia can occur when elevated levels of PTH, as seen in primary hyperparathyroidism (PHPT), or elevated levels of PTHrP, as seen in humoral hypercalcemia of malignancy (HHM), lead to excessive activation of the PTH1R. A monoclonal antibody against PTH1R is being developed to reverse hypercalcemia in these conditions.

Target Parathyroid hormone 1 receptor (PTH1R)
Drug Modality Monoclonal antibody
Indication Hypercalcemia; Hyperparathyroidism
Product Category Biologic
Mechanism of Action PTH1R antagonists
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.